Yes, semaglutide, the drug in Ozempic, is a peptide: a lab-modified copy of the human hormone GLP-1, carrying two amino acid swaps and a fatty acid tail bolted on to keep it from vanishing within minutes. That modification is the whole story of why a hormone your gut already makes every day had to be re-engineered before it could work as a once-weekly injection. The randomized trial evidence behind what it does once it’s in your system is about as strong as peptide pharmacology gets, and the gaps in that evidence are specific enough to name rather than wave at.
What makes semaglutide a peptide
Semaglutide is a synthetic analogue of human GLP-1 (glucagon-like peptide-1), the gut hormone that tells your pancreas to release insulin after a meal. Lau and colleagues, who designed the molecule, describe it plainly: semaglutide carries two amino acid substitutions relative to native GLP-1, at positions 8 and 34, plus a fatty acid chain attached at lysine 26 that lets it grab onto circulating albumin.[1]
That is not cosmetic chemistry. It is the entire reason the drug exists.
The problem it solves: native GLP-1 barely survives contact with your bloodstream. Lund, Knop and Vilsbøll put a number on it: about two minutes, the time it takes the enzyme DPP-4 to chew up circulating GLP-1 after your gut releases it.[2] A hormone with a two-minute half-life cannot be dosed once a week, or even once a day.
2 minutes: native GLP-1's circulating half-life before DPP-4 degrades it PMID 24694879
The two substitutions and the albumin-binding tail change that math. Albumin is one of the most abundant proteins in blood, and binding to it gives the modified peptide somewhere to hide from DPP-4 between doses, stretching its effective action from minutes to a week.[1] Insulin ran into a version of the same problem decades earlier: unmodified insulin also degrades too fast for practical dosing, which is why formulators attached fatty acid chains or crystallized it with protamine just to get multi-hour, let alone multi-day, action. Semaglutide’s albumin trick is a newer answer to an old peptide-drug problem.
Two amino acid swaps and a fatty acid tail turn a two-minute hormone into a once-weekly drug.
What the randomized trials show
Wilding and colleagues ran the trial that put semaglutide on the map for weight loss. In STEP 1, 1,961 adults with overweight or obesity, none of them diabetic, were randomly assigned to 2.4 mg semaglutide weekly or a matched placebo, on top of lifestyle counseling, for 68 weeks.[3] The result was not subtle.
-14.9% average body weight change at 68 weeks with semaglutide, vs -2.4% with placebo PMID 33567185
That is a randomized, double-blind, placebo-controlled design, the only kind of study that can show the drug caused the difference rather than something else about the people who took it.[3]
STEP 1 wasn’t semaglutide’s first trial. Sorli and colleagues had already established its glucose-lowering effect in type 2 diabetes years earlier, in SUSTAIN 1, before the same peptide was tested at a higher dose purely for weight.[4] The obesity indication is the sequel. The diabetes indication is the original.
What the evidence does not establish
Three gaps matter more than the rest.
Long-term use beyond the trial windows. STEP 1 ran 68 weeks. The cardiovascular outcomes trial that Lincoff and colleagues published followed people for a mean of about three years.[5] Nobody has run a randomized, placebo-controlled trial of a full decade of continuous semaglutide use, so claims about what ten years on the drug does are extrapolation.
Association is not causation, and the field’s own retrospective data show why that distinction matters. Ipaye and colleagues matched 64,178 pairs of people with type 2 diabetes and obesity, comparing those started on semaglutide against those started on a DPP-4 inhibitor. People on semaglutide had lower rates of some obesity-linked cancers.[6]
Cancer incidence with semaglutide vs a DPP-4 inhibitor
Composite obesity-linked cancer: 0.88
Colorectal: 0.8
Liver: 0.75
Pancreatic: 0.76
Hazard ratios from a retrospective cohort of 64,178 propensity-matched pairs. Below 1.0 means a lower observed rate in the semaglutide group. This is an observed association from a cohort study.
An association is not a proven effect. A retrospective cohort study, however large, cannot rule out that people who tolerate semaglutide well, stay on it, and lose weight also differ from DPP-4 inhibitor users in ways that independently affect cancer risk. Nobody has randomized people to semaglutide versus placebo with cancer incidence as the primary endpoint. Until someone does, “associated with lower rates” is the honest way to describe this finding.
Weight loss doesn’t stick without the drug. Wilding and colleagues followed STEP 1 participants after they stopped semaglutide and found the weight came back.[7] Whatever mechanism drives the loss, it depends on the peptide staying in your system.
Dosing as it appears in the research
Two things stand out here, and neither is a recommendation.
Real-world titration lags the trial protocol. Samuels and colleagues tracked 2,306 patients at an academic obesity clinic and found that while 81% of semaglutide users escalated to at least 1 mg, only 23% ever reached the 2.4 mg dose used in STEP 1.[8] Median treatment persistence in that cohort was about eleven months. Trial results describe what happens when people follow the trial’s schedule. Most people, it turns out, don’t.
The diabetes and weight-management doses are not the same product. Frías and colleagues ran SUSTAIN FORTE specifically to test whether pushing the type 2 diabetes dose from 1.0 mg to 2.0 mg weekly helped, and it did, modestly: extra HbA1c reduction and extra weight loss, at the cost of similar gastrointestinal side effects.[9] Two mg is the ceiling that trial tested for diabetes control. The weight-management formulation goes further still, to the 2.4 mg dose used throughout STEP 1.
Side effects and red flags
Gastrointestinal symptoms are the main tax. In STEP 1, nausea and diarrhea were the most common adverse events, usually transient and mild to moderate, but gastrointestinal problems drove far more dropouts on semaglutide than on placebo (4.5% vs 0.8%).[3]
Gallbladder problems tick up too. In a dedicated safety analysis of the cardiovascular outcomes trial, Kushner and colleagues found gallbladder-related disorders, mostly cholelithiasis, in 2.8% of the semaglutide group versus 2.3% on placebo.[10]
The thyroid warning is a rodent story with an asterisk. Bjerre Knudsen and colleagues did this work with liraglutide rather than semaglutide, but it became the basis for the whole class warning: the thyroid C-cell tumor warning that semaglutide carries as a member of the GLP-1 receptor agonist class rests on rodent data showing that GLP-1 receptor agonists activate thyroid C-cells and cause calcitonin release and C-cell proliferation in rats and mice; the same research found that humans and monkeys have far lower GLP-1 receptor expression in thyroid C-cells, and that high-dose, long-term treatment did not cause C-cell hyperplasia in monkeys, so whether the effect occurs in humans is unresolved; and because of that rodent signal, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are excluded from treatment.[11]
Bottom line on safety: the adverse events with real trial numbers behind them, nausea, diarrhea, gallstones, are common and usually manageable. The one people worry about most, thyroid tumors, is built on a species-specific rodent signal that has not been confirmed, or ruled out, in humans.
Where semaglutide sits against tirzepatide and everything else sold as a peptide
Semaglutide is not the last word in this drug class, and it is not the strongest performer within it.
Nauck and D’Alessio’s review lays out the comparison plainly: tirzepatide, which activates both the GIP and GLP-1 receptors rather than GLP-1 alone, produced significantly larger HbA1c and weight reductions than semaglutide dosed at 1 mg weekly in head-to-head trials in people with type 2 diabetes.[12] That comparison used semaglutide’s lower diabetes-dose strength, well below the 2.4 mg weight-management dose used in STEP 1, so treat the size of the gap with some caution. The direction still holds up.
Where the evidence stands, by compound
Compound | Receptor target | Trial evidence |
|---|---|---|
Semaglutide | GLP-1 only | Multiple randomized, placebo-controlled trials in diabetes and obesity |
Tirzepatide | GIP and GLP-1 | Outperformed semaglutide 1 mg weekly in randomized head-to-head trials |
Most online research peptides | Varies (GH axis, IGF-1 axis) | No regulatory approval; a far thinner clinical evidence base |
Diabetes-dose comparisons unless noted.
Compare that to what gets sold as “research peptides” outside a pharmacy. Dominikowski and colleagues reviewed the growth hormone secretagogues, GHRH analogues and IGF-1 analogues that circulate under compound names online, and their finding is blunt: none of it has regulatory approval, and the clinical evidence base is thin next to drugs that went through an actual phase 3 program.[13] If you want to see which peptide claims survive contact with a human trial, look past semaglutide, which cleared that bar years ago, toward GHK-Cu, whose evidence base drops off a cliff the moment you leave the skin.
What to watch: the injectable version isn’t the endpoint of this research program. Knop and colleagues ran OASIS 1, testing a 50 mg oral semaglutide tablet, five times the strength of the existing diabetes pill, specifically to see whether an oral formulation could approach the injectable’s weight-loss effect.[14] If that program matures, the needle stops being part of the story.
So yes, Ozempic is a peptide, full stop. It is a two-amino-acid edit and a fatty acid tail away from a hormone your body already destroys within two minutes. The randomized trial evidence behind what happens once it’s in your system is about as solid as peptide pharmacology gets. The open question is what happens after year three, a stretch no trial has run long enough to cover.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.. Journal of medicinal chemistry, 2015.
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.. European journal of internal medicine, 2014.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.. The lancet. Diabetes & endocrinology, 2017.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.. The New England journal of medicine, 2023.
Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.. Diabetes, obesity & metabolism, 2025.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, obesity & metabolism, 2022.
Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.. Diabetes, obesity & metabolism, 2025.
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.. The lancet. Diabetes & endocrinology, 2021.
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.. Obesity (Silver Spring, Md.), 2025.
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.. Endocrinology, 2010.
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.. Cardiovascular diabetology, 2022.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Frontiers in endocrinology, 2026.
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England), 2023.
